Tardive Dyskinesia: Underlying Mechanism

Stacy Finkbeiner, US Medical Director at Teva Pharmaceuticals, explains the underlying pathophysiological mechanism that drives tardive dyskinesia. She is one of the authors of the study, Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.
See the full-text article: bit.ly/3Ov5qkJ
Presented by The Journal of Clinical Psychiatry ​ @psychiatristcns